Rule Recognizing Privileged Communications Between Clients and Patent Practitioners at the Patent Trial and Appeal Board, 71653-71657 [2016-25141]
Download as PDF
Federal Register / Vol. 81, No. 201 / Tuesday, October 18, 2016 / Proposed Rules
Unless we certify that a rule will not
have a significant economic impact on
a substantial number of small entities,
the Regulatory Flexibility Act requires
us to analyze regulatory options to
minimize any significant economic
impact of a regulation on small entities.
Most pharmacies meet the Small
Business Administration definition of a
small entity, which is defined as having
annual sales less than $25.5 million for
this industry. We are not aware of any
routine compounding of these drug
products and do not estimate any
compliance costs or loss of sales to
small businesses as a result of the
prohibition against compounding these
drug products. Therefore, we propose to
certify that this proposed rule will not
have a significant economic impact on
a substantial number of small entities.
VII. Paperwork Reduction Act of 1995
FDA tentatively concludes that this
proposed rule contains no collection of
information. Therefore, clearance by the
Office of Management and Budget under
the Paperwork Reduction Act of 1995 is
not required.
Lhorne on DSK30JT082PROD with PROPOSALS
VIII. Federalism
We have analyzed this proposed rule
in accordance with the principles set
forth in Executive Order 13132. We
have determined that this proposed rule
does not contain policies that have
substantial direct effects on the States,
on the relationship between the
National Government and the States, or
on the distribution of power and
responsibilities among the various
levels of government. Accordingly, we
conclude that the rule does not contain
policies that have federalism
implications as defined in the Executive
order and, consequently, a federalism
summary impact statement is not
required.
IX. References
The following references are on
display in the Division of Dockets
Management (see ADDRESSES) and are
available for viewing by interested
persons between 9 a.m. and 4 p.m.,
Monday through Friday; they are also
available electronically at https://
www.regulations.gov. FDA has verified
the Web site addresses, as of the date
this document publishes in the Federal
Register, but Web sites are subject to
change over time.
1. Mangano, D.T., I.C. Tudor, and C. Dietzel,
‘‘The Risk Associated With Aprotinin in
Cardiac Surgery,’’ New England Journal
of Medicine, 354(4):353–365, 2006.
2. FDA News Release, ‘‘FDA Issues Public
Health Advisory for Trasylol’’ (February
8, 2006), available at https://www.fda.gov/
VerDate Sep<11>2014
12:33 Oct 17, 2016
Jkt 241001
NewsEvents/Newsroom/
PressAnnouncements/2006/
ucm108592.htm.
3. Schneeweiss, S., J.D. Seeger, J. Landon,
and A.M. Walker, ‘‘Aprotinin During
Coronary-Artery Bypass Grafting and
Risk of Death,’’ New England Journal of
Medicine, 358:771–783, 2008.
4. Mangano, D.T., Y. Miao, A. Vuylsteke, et
al., ‘‘Mortality Associated With
Aprotinin During 5 Years Following
Coronary Artery Bypass Graft Surgery,’’
Journal of the American Medical
Association, 297(5):471–479, 2007.
´
5. Fergusson, D.A., P.C. Hebert, C.D. Mazer,
et al., ‘‘A Comparison of Aprotinin and
Lysine Analogues in High-Risk Cardiac
Surgery,’’ New England Journal of
Medicine, 358(22):2319–2331, 2008.
6. FDA Alert—Aprotinin Injection (Marketed
as Trasylol) (October 25, 2007), available
at https://www.fda.gov/Safety/MedWatch/
SafetyInformation/SafetyAlertsfor
HumanMedicalProducts/
ucm150815.htm.
7. FDA News Release, ‘‘FDA Requests
Marketing Suspension of Trasylol’’
(November 5, 2007), available at https://
www.fda.gov/NewsEvents/Newsroom/
PressAnnouncements/2007/
ucm109021.htm.
8. FDA News Release, ‘‘Manufacturer
Removes Remaining Stocks of Trasylol
Access Limited to Investigational Use’’
(May 14, 2008), available at https://
www.fda.gov/NewsEvents/Newsroom/
PressAnnouncements/2008/
ucm116895.htm.
9. FDA–PARLODEL (bromocriptine mesylate)
Information, available at https://
www.fda.gov/downloads/Advisory
Committees/CommitteesMeeting
Materials/Drugs/PharmacyCompounding
AdvisoryCommittee/UCM449535.pdf.
10. FDA Fertility and Maternal Health Drugs
Advisory Committee Meeting Minutes
(June 1 and 2, 1989), available at https://
www.fda.gov/downloads/Advisory
Committees/CommitteesMeeting
Materials/Drugs/PharmacyCompounding
AdvisoryCommittee/UCM449535.pdf.
11. FDA Drug Safety Communication—
Abnormal Heart Rhythms May Be
Associated with Use of Zofran
(Ondansetron)(September 15, 2011),
available at https://www.fda.gov/Drugs/
DrugSafety/ucm271913.htm.
12. FDA Drug Safety Communication—New
Information Regarding QT Prolongation
with Ondansetron (Zofran) (June 29,
2012), available at https://www.fda.gov/
Drugs/DrugSafety/ucm310190.htm.
13. FDA Drug Safety Communication—
Updated Information on 32 mg
Intravenous Ondansetron (Zofran) Dose
and Pre-Mixed Ondansetron Products
(December 4, 2012), available at https://
www.fda.gov/Drugs/DrugSafety/
ucm330049.htm.
List of Subjects in 21 CFR Part 216
Drugs, Prescription drugs.
Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
PO 00000
Frm 00010
Fmt 4702
Sfmt 4702
71653
of Food and Drugs, it is proposed that
21 CFR part 216 be amended as follows:
PART 216—HUMAN DRUG
COMPOUNDING
1. The authority citation for part 216
continues to read as follows:
■
Authority: 21 U.S.C. 351, 352, 353a, 353b,
355, and 371.
2. Amend § 216.24 by adding, in
alphabetical order, to the list of drugs
‘‘Aprotinin’’, ‘‘Bromocriptine mesylate’’,
and ‘‘Ondansetron hydrochloride’’ to
read as follows:
■
§ 216.24 Drug products withdrawn or
removed from the market for reasons of
safety or effectiveness.
*
*
*
*
*
Aprotinin: All drug products
containing aprotinin.
*
*
*
*
*
Bromocriptine mesylate: All drug
products containing bromocriptine
mesylate for prevention of physiological
lactation.
*
*
*
*
*
Ondansetron hydrochloride: All
intravenous drug products containing
greater than a 16 milligram single dose
of ondansetron hydrochloride.
*
*
*
*
*
Dated: October 11, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–25005 Filed 10–17–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF COMMERCE
United States Patent and Trademark
Office
37 CFR Part 42
[Docket No. PTO–P–2016–0029]
RIN 0651–AD10
Rule Recognizing Privileged
Communications Between Clients and
Patent Practitioners at the Patent Trial
and Appeal Board
Patent Trial and Appeal Board,
United States Patent and Trademark
Office, U.S. Department of Commerce.
ACTION: Proposed rule.
AGENCY:
This proposed rule would
amend the rules of practice before the
Patent Trial and Appeal Board to
recognize that, in connection with
discovery conducted in certain
proceedings at the United States Patent
and Trademark Office (USPTO or
Office), communications between U.S.
SUMMARY:
E:\FR\FM\18OCP1.SGM
18OCP1
Lhorne on DSK30JT082PROD with PROPOSALS
71654
Federal Register / Vol. 81, No. 201 / Tuesday, October 18, 2016 / Proposed Rules
patent agents or foreign patent
practitioners and their clients are
privileged to the same extent as
communications between clients and
U.S. attorneys. The rule would apply to
inter partes review, post-grant review,
the transitional program for covered
business method patents, and derivation
proceedings. This rule would clarify the
protection afforded to such
communications, which is currently not
addressed in the rules governing Board
proceedings at the USPTO. This new
rule will not affect the duty of
disclosure and candor before the Office
under 37 CFR 1.56.
DATES: Comment date: The Office
solicits comments from the public on
this proposed rulemaking. Written
comments must be received on or before
December 19, 2016 to ensure
consideration.
ADDRESSES: Comments should be sent
by electronic mail message over the
Internet addressed to:
acprivilege@uspto.gov. Comments may
also be submitted by postal mail
addressed to: Mail Stop OPIA Director
of the United States Patent and
Trademark Office, P.O. Box 1450,
Alexandria, VA 22313–1450, marked to
the attention of ‘‘Soma Saha, Patent
Attorney, Patent Trial Proposed Rule on
Privilege.’’
Comments may also be sent by
electronic mail message over the
Internet via the Federal eRulemaking
Portal at https://www.regulations.gov.
See the Federal eRulemaking Portal Web
site for additional instructions on
providing comments via the Federal eRulemaking Portal.
Although comments may be
submitted by postal mail, the Office
prefers to receive comments by
electronic mail message to be able to
more easily share all comments with the
public. The Office prefers the comments
to be submitted in plain text, but also
accepts comments submitted in
ADOBE® portable document format or
MICROSOFT WORD® format.
Comments not submitted electronically
should be submitted on paper in a
format that accommodates digital
scanning into ADOBE® portable
document format.
The comments will be available for
public inspection at the Office of Policy
and International Affairs, currently
located in Madison East, Second Floor,
600 Dulany Street, Alexandria, Virginia.
Comments also will be available for
viewing via the Office’s Internet Web
site at https://www.uspto.gov/patents/
law/comments/index.jsp and at https://
www.regulations.gov. Because
comments will be made available for
VerDate Sep<11>2014
12:33 Oct 17, 2016
Jkt 241001
public inspection, information that the
submitter does not desire to be made
public, such as address or phone
number, should not be included in the
comments.
FOR FURTHER INFORMATION CONTACT:
Soma Saha, Patent Attorney, by email at
soma.saha@uspto.gov or by telephone at
(571) 272–8652; or Edward Elliott,
Attorney Advisor, by email at
edward.elliott@uspto.gov or by
telephone at (571) 272–7024.
SUPPLEMENTARY INFORMATION:
Purpose: This proposed rule would
amend the rules of practice before the
Patent Trial and Appeal Board (PTAB)
to recognize that communications
between non-attorney U.S. patent agents
or foreign patent practitioners and their
clients that pertain to authorized
practice before the United States Patent
and Trademark Office (Office or
USPTO) are privileged to the same
extent as communications of that sort
conducted between clients and U.S.
attorneys. Under the proposed rule,
those communications would be
protected from discovery in trial
practice proceedings at the USPTO. The
proposed rule would apply to inter
partes review (IPR), post-grant review
(PGR), the transitional program for
covered business method patents
(CBM), and derivation proceedings.
Currently, the rules governing
proceedings at the USPTO do not
address the privilege of communications
with patent practitioners, and questions
regarding that matter are decided on a
case-by-case basis under common law
principles. This new rule will not affect
the duty of disclosure and candor before
the Office under 37 CFR 1.56.
Background: Within this notice, the
term ‘‘patent practitioner’’ includes both
those authorized to practice patent
matters before the USPTO and those
authorized to practice patent matters in
foreign jurisdictions. When referring to
these groups separately, the terms ‘‘U.S.
or domestic patent practitioners’’ and
‘‘foreign patent practitioners’’ will be
used, respectively.
In February 2015, the USPTO held a
roundtable and solicited comments on
attorney-client privilege issues. See
Notice of Roundtable and Request for
Comments on Domestic and
International Issues Related to
Privileged Communications Between
Patent Practitioners and Their Clients,
80 FR 3953 (Jan. 26, 2015). As part of
that process, the USPTO requested
comments on whether it should
recognize that communications between
patent applicants and owners and their
U.S. patent agents or foreign patent
practitioners are privileged to the same
PO 00000
Frm 00011
Fmt 4702
Sfmt 4702
extent as communications between U.S.
patent attorneys and patent applicants
and owners. Respondents unanimously
supported a rule recognizing such
privilege. See USPTO, Summary of
Roundtable and Written Comments,
available at https://www.uspto.gov/sites/
default/files/documents/Summary%20
of%20Privileged%20
Communication%20Roundtable.pdf
(‘‘Privilege Report’’).
The USPTO administers various
proceedings that entail discovery
procedures, namely the IPR, PGR, and
transitional program for CBM patents. In
addition, the derivation proceedings
provided for by the Leahy-Smith
America Invents Act, Public Law 112–
29, 125 Stat. 284 (2011) (AIA) permit
discovery. Questions regarding privilege
issues may arise in the course of
discovery, and as some roundtable
commenters noted, rules regarding
privilege for U.S. patent agents and
foreign practitioners during discovery in
PTAB proceedings are not well defined.
Current Practice: PTAB proceedings
are subject to the Federal Rules of
Evidence (FRE), which include rules on
attorney-client privilege. See 37 CFR
42.62(a). Accordingly, privilege may be
asserted in PTAB proceedings by
licensed attorneys. However, the FRE
does not explicitly address privilege for
communications with non-attorney U.S.
patent agents or with foreign patent
practitioners.
The rules governing PTAB practice
likewise do not address this matter, and
when it arises, PTAB Administrative
Law Judges make legal determinations
as to which communications may be
protected from disclosure on a case-bycase basis, based on common law. See
GEA Process Engineering, Inc. v.
Steuben Foods, Inc., IPR2014–00041,
Paper 117 (PTAB 2014). U.S. courts
have devised several different
approaches to determine under what
circumstances communications with
these practitioners are privileged. As the
Privilege Report notes, the common law
on privilege for domestic and foreign
patent practitioners varies across
jurisdictions. Different approaches are
taken, and results sometimes conflict.
This may lead to administrative
inefficiencies and inconsistencies in
outcomes, as PTAB must select which
set of common law rules to follow. (It is
also noted that Administrative Law
Judges in other agencies recognize
certain confidential communications
with a patent agent as privileged. See,
e.g., USITC Inv. No. 337–TA–339, slip
op. at 2, 1992 WL 811804 (ITC 1992)
(finding that confidential
communications between a U.S. patent
agent and his client in connection with
E:\FR\FM\18OCP1.SGM
18OCP1
Lhorne on DSK30JT082PROD with PROPOSALS
Federal Register / Vol. 81, No. 201 / Tuesday, October 18, 2016 / Proposed Rules
a patent prosecution are privileged).)
The Federal Circuit recently recognized
that attorney-client privilege applies to
U.S. patent agents acting within the
scope of their authorized practice. See
In re Queen’s University at Kingston,
PARTEQ Research and Development
Innovations, No. 2015–145 (Fed. Cir.
2016).
The Office has strong policy reasons
to establish a privilege rule governing
trial proceedings before PTAB. Such a
rule would help ensure consistent
outcomes with respect to privilege
matters that arise at the Office, would
improve public understanding of how
privilege questions are decided before
PTAB, and would help further judicial
economy by providing PTAB judges
with a clear, concise statement of when
privilege applies.
Public Comments: In August 2015, the
USPTO published in the Federal
Register a proposed rule amending the
rules for trial practice before the Office.
See Amendments to the Rules of
Practice for Trials Before the Patent
Trial and Appeal Board, 80 FR 50719
(Aug. 20, 2015). Included in that
proposed rule was a request for
comments on the advisability of a
privilege rule for PTAB proceedings.
The comments submitted in response to
that request are available on the USPTO
Web site at https://www.uspto.gov/
patents-application-process/patenttrial-and-appeal-board/commentsamendments-rules-practice-trials.
Those responding to the request
universally agreed that a privilege rule
for PTAB proceedings should be
promulgated. Respondents
overwhelmingly favored promulgating
such a rule, with some noting that it
would lead to clarity and consistency
and ‘‘can reduce uncertainty and
mitigate discovery costs.’’ See Letter
from Frederick W. Mau II on behalf of
Toyota Motor Corp., David B. Kelley on
behalf of Ford Motor Co., and Mark
Duell on behalf of American Honda
Motor Co., Inc., RE: Comments on
Amendments to the Rules of Practice for
Trials Before the Patent Trial and
Appeal Board, p. 4–5 (Oct. 16, 2015).
Others suggested that ‘‘[i]f patent agents
are not entitled to have their
communications be considered
privileged, however, then their utility—
and associated cost savings for
stakeholders—is lost.’’ See Letter from
Sharon A. Israel, President of the
American Intellectual Property Law
Assoc., RE: Response to Proposed
‘‘Amendments to the Rules of Practice
for Trials Before the Patent Trial and
Appeal Board,’’ 80 FR 50720 (August
20, 2015), p. 15–16 (Oct. 21, 2015).
VerDate Sep<11>2014
12:33 Oct 17, 2016
Jkt 241001
Commenters said it ‘‘would be
particularly useful for patent agents[’]
communications to be explicitly
protected in the discovery rules for postgrant proceedings (e.g., inter parties [sic]
review) before the USPTO.’’ See Letter
from Dorothy R. Auth, President of the
New York Intellectual Property Law
Assoc., RE: NYIPLA Comments in
Response to ‘‘Amendments to the Rules
of Practice for Trials Before the Patent
Trial and Appeal Board,’’ Federal
Register Notice, August 20, 2015, Vol.
80, No. 161 (80 FR 50720), p. 6–9 (Nov.
18, 2015). Commenters suggested that
the rule should extend at least to
communications made in connection
with acts that patent agents are
authorized to perform in their particular
jurisdictions, such as prosecuting patent
applications. The USPTO agrees that the
scope of a privilege rule should be
defined by the activities that the agent
is authorized to carry out. Others
suggested that it should be ‘‘a simple
rule . . . that explicitly recognize[s]
privilege for communications between
patent applicants or owners and their
domestic patent agents or foreign
professional patent practitioners under
the same circumstances as such
privilege is recognized for
communications between applicants or
owners and U.S. attorneys.’’ See Letter
from Andrew D. Meikle, President of the
U.S. Section of the International
Federation of Intellectual Property
Attorneys (FICPI), RE: Comments on
‘‘Recognizing Privilege for
Communications With Domestic Patent
Agents and Foreign Patent
Practitioners’’, p. 4 (Nov. 24, 2015).
According to these comments, ‘‘[t]his
approach would provide the greatest
uniformity and certainty, and avoid the
need for the PTAB to engage in complex
fact based analysis regarding application
of the privilege under the common
law.’’ Id. These views were echoed by
a law professor who has studied this
issue since 2008:
The privilege should be as broad as the
ordinary attorney-client privilege. It should
cover not only U.S. patent agents, but also
foreign legal representatives. While the best
solution would be a privilege that applied in
all legal tribunals—not only the PTAB, but
also federal and state courts—adoption of a
privilege only for the PTAB would be a
valuable first step toward this goal.
See Letter from John T. Cross, Professor
of Law at University of Louisville,
Possible Adoption of a Legal
Representation Privilege in Matters
Before the Patent Trial and Appeal
Board, p. 2 (Sep. 9, 2015).
The USPTO agrees with these views
and believes the proposed rule reflects
them. As a policy matter, open and
PO 00000
Frm 00012
Fmt 4702
Sfmt 4702
71655
frank discussions between practitioners
and clients promotes effective legal
representation before the Office.
Discussion of Specific Rules
Taking into consideration comments
from the public and insight gained from
practice, the Office proposes to amend
37 CFR 42 to add new section 42.57 that
clarifies which patent practitioners are
eligible for assertions of attorney-client
privilege.
The term ‘‘patent practitioner’’ is used
to conform with existing terminology
and avoid confusion with other terms
used around the world, such as ‘‘IP
Advisor’’ or ‘‘Patent Advisor.’’ It fits
with practice elsewhere in Title 37,
which refers to domestic ‘‘patent
practitioners,’’ i.e., U.S. patent agents
and patent attorneys registered under 37
CFR 11.6. This narrower meaning is
appropriate for most sections of Title 37,
which deal with practitioners admitted
to practice before the USPTO. For the
new rule only, the term also includes
comparable foreign counterparts
practicing before foreign patent offices.
The rule would provide that the
privilege only applies where the
practitioner performs legal work
authorized by the jurisdiction in which
the practitioner practices. For instance,
communications between clients and
U.S. patent agents relating to patent
application matters would be protected
as privileged under the rule, but
communications between these parties
regarding litigation strategies would not
be protected. The proposed rule also
does not recognize privilege as applying
to advice given by lay persons in
jurisdictions that do not impose
professional qualifications as a
requirement to practice. However, the
proposed rule can apply to
communications from an in-house
counsel who performs the functions of
a patent attorney under appropriate
circumstances, even though some civil
law jurisdictions may not grant in-house
counsel the privilege-type protections
given to attorneys.
The Office invites the public to
provide any comments on the proposed
rule to inform further action.
Costs and Benefits: This rulemaking is
not economically significant, and is not
significant, under Executive Order
12866 (Sept. 30, 1993), as amended by
Executive Order 13258 (Feb. 26, 2002)
and Executive Order 13422 (Jan. 18,
2007).
Rulemaking Considerations
A. Administrative Procedure Act (APA)
This proposed rule revises the rules of
practice before PTAB to recognize that
E:\FR\FM\18OCP1.SGM
18OCP1
71656
Federal Register / Vol. 81, No. 201 / Tuesday, October 18, 2016 / Proposed Rules
Lhorne on DSK30JT082PROD with PROPOSALS
communications between non-attorney
or foreign patent practitioners and their
clients that pertain to authorized
practice before the USPTO are
privileged. The changes in this
rulemaking involve rules of agency
practice and procedure and/or
interpretive rules. See Nat’l Org. of
Veterans’ Advocates v. Secretary of
Veterans Affairs, 260 F.3d 1365, 1375
(Fed. Cir. 2001) (rule that clarifies
interpretation of a statute is
interpretive); Bachow Commc’ns Inc. v.
F.C.C., 237 F.3d 683, 690 (D.C. Cir.
2001) (rules governing an application
process are procedural under the
Administrative Procedure Act); Inova
Alexandria Hosp. v. Shalala, 244 F.3d
342, 350 (4th Cir. 2001) (rules for
handling appeals were procedural
where they did not change the
substantive requirements for reviewing
claims).
Accordingly, prior notice and
opportunity for public comment are not
required pursuant to 5 U.S.C. 553(b) or
(c), or any other law. See Cooper Techs.
Co. v. Dudas, 536 F.3d 1330, 1336–37
(Fed. Cir. 2008) (stating that 5 U.S.C.
553, and thus 35 U.S.C. 2(b)(2)(B), do
not require notice and comment
rulemaking for ‘‘interpretative rules,
general statements of policy, or rules of
agency organization, procedure, or
practice’’ (quoting 5 U.S.C. 553(b)(A))).
However, the Office chose to seek
public comment before implementing
the rule to benefit from the public’s
input.
B. Regulatory Flexibility Act
For the reasons set forth herein, the
Deputy General Counsel for General
Law of the USPTO has certified to the
Chief Counsel for Advocacy of the Small
Business Administration that this
proposed rule will not have a significant
economic impact on a substantial
number of small entities. See 5 U.S.C.
605(b).
The changes proposed in this rule are
to revise the rules of practice before
PTAB to explicitly recognize that
communications between non-attorney
or foreign patent practitioners and their
clients that pertain to authorized
practice before the USPTO or foreign
patent offices are privileged and to
define those persons who may avail
themselves of this privilege. These
proposed changes are expected to create
no additional burden to those practicing
before the Board as this rule merely
clarifies rights and protections for the
practitioner and client and does not
impose a change in practice or
requirements. In fact, this rule may
produce a small benefit from a
reduction in uncertainty and mitigation
VerDate Sep<11>2014
12:33 Oct 17, 2016
Jkt 241001
of discovery costs. For the foregoing
reasons, the changes proposed in this
rule will not have a significant
economic impact on a substantial
number of small entities.
C. Executive Order 12866 (Regulatory
Planning and Review)
This rulemaking has been determined
to be not significant for purposes of
Executive Order 12866 (Sept. 30, 1993).
D. Executive Order 13563 (Improving
Regulation and Regulatory Review)
The Office has complied with
Executive Order 13563. Specifically, the
Office has, to the extent feasible and
applicable: (1) Made a reasoned
determination that the benefits justify
the costs of the rule; (2) tailored the rule
to impose the least burden on society
consistent with obtaining the regulatory
objectives; (3) selected a regulatory
approach that maximizes net benefits;
(4) specified performance objectives; (5)
identified and assessed available
alternatives; (6) involved the public in
an open exchange of information and
perspectives among experts in relevant
disciplines, affected stakeholders in the
private sector and the public as a whole,
and provided on-line access to the
rulemaking docket; (7) attempted to
promote coordination, simplification,
and harmonization across government
agencies and identified goals designed
to promote innovation; (8) considered
approaches that reduce burdens and
maintain flexibility and freedom of
choice for the public; and (9) ensured
the objectivity of scientific and
technological information and
processes.
E. Executive Order 13132 (Federalism)
This rulemaking does not contain
policies with federalism implications
sufficient to warrant preparation of a
Federalism Assessment under Executive
Order 13132 (Aug. 4, 1999).
F. Executive Order 13175 (Tribal
Consultation)
This rulemaking will not: (1) Have
substantial direct effects on one or more
Indian tribes; (2) impose substantial
direct compliance costs on Indian tribal
governments; or (3) preempt tribal law.
Therefore, a tribal summary impact
statement is not required under
Executive Order 13175 (Nov. 6, 2000).
G. Executive Order 13211 (Energy
Effects)
This rulemaking is not a significant
energy action under Executive Order
13211 because this rulemaking is not
likely to have a significant adverse effect
on the supply, distribution, or use of
PO 00000
Frm 00013
Fmt 4702
Sfmt 4702
energy. Therefore, a Statement of Energy
Effects is not required under Executive
Order 13211 (May 18, 2001).
H. Executive Order 12988 (Civil Justice
Reform)
This rulemaking meets applicable
standards to minimize litigation,
eliminate ambiguity, and reduce burden
as set forth in sections 3(a) and 3(b)(2)
of Executive Order 12988 (Feb. 5, 1996).
I. Executive Order 13045 (Protection of
Children)
This rulemaking does not concern an
environmental risk to health or safety
that may disproportionately affect
children under Executive Order 13045
(Apr. 21, 1997).
J. Executive Order 12630 (Taking of
Private Property)
This rulemaking will not affect a
taking of private property or otherwise
have taking implications under
Executive Order 12630 (Mar. 15, 1988).
K. Congressional Review Act
Under the Congressional Review Act
provisions of the Small Business
Regulatory Enforcement Fairness Act of
1996 (5 U.S.C. 801 et seq.), prior to
issuing any final rule, the USPTO will
submit a report containing the rule and
other required information to the United
States Senate, the United States House
of Representatives, and the Comptroller
General of the Government
Accountability Office. The changes in
this final rule are not expected to result
in an annual effect on the economy of
100 million dollars or more, a major
increase in costs or prices, or significant
adverse effects on competition,
employment, investment, productivity,
innovation, or the ability of United
States-based enterprises to compete
with foreign-based enterprises in
domestic and export markets. Therefore,
this final rule is not a ‘‘major rule’’ as
defined in 5 U.S.C. 804(2).
L. Unfunded Mandates Reform Act of
1995
The changes set forth in this
rulemaking do not involve a Federal
intergovernmental mandate that will
result in the expenditure by State, local,
and tribal governments, in the aggregate,
of 100 million dollars (as adjusted) or
more in any one year, or a Federal
private sector mandate that will result
in the expenditure by the private sector
of 100 million dollars (as adjusted) or
more in any one year, and will not
significantly or uniquely affect small
governments. Therefore, no actions are
necessary under the provisions of the
E:\FR\FM\18OCP1.SGM
18OCP1
Federal Register / Vol. 81, No. 201 / Tuesday, October 18, 2016 / Proposed Rules
Unfunded Mandates Reform Act of
1995. See 2 U.S.C. 1501 et seq.
M. National Environmental Policy Act
This rulemaking will not have any
effect on the quality of the environment
and is thus categorically excluded from
review under the National
Environmental Policy Act of 1969. See
42 U.S.C. 4321 et seq.
N. National Technology Transfer and
Advancement Act
The requirements of section 12(d) of
the National Technology Transfer and
Advancement Act of 1995 (15 U.S.C.
272 note) are not applicable because this
rulemaking does not contain provisions
which involve the use of technical
standards.
O. Paperwork Reduction Act
The Paperwork Reduction Act of 1995
(44 U.S.C. 3501–3549) requires that the
Office consider the impact of paperwork
and other information collection
burdens imposed on the public. This
proposed rule not does not involve any
new information collection
requirements that are subject to review
by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501–
3549). Any information collections
associated with this rule have been
previously approved under OMB
control number 0651–0069.
Notwithstanding any other provision
of law, no person is required to respond
to, nor shall any person be subject to, a
penalty for failure to comply with a
collection of information subject to the
requirements of the Paperwork
Reduction Act unless that collection of
information displays a currently valid
OMB control number.
List of Subjects in 37 CFR Part 42
Administrative practice and
procedure, inventions and patents.
For the reasons set forth in the
preamble, 37 CFR part 42 is proposed to
be amended as follows:
PART 42—TRIAL PRACTICE BEFORE
THE PATENT TRIAL AND APPEAL
BOARD
1. The authority citation for 37 CFR
Part 42 continues to read as follows:
Lhorne on DSK30JT082PROD with PROPOSALS
■
Authority: 35 U.S.C. 2(b)(2), 6, 21, 23, 41,
135, 311, 312, 316, 321–326; Pub. L. 112–29,
125 Stat. 284; and Pub. L. 112–274, 126 Stat.
2456.
■
2. Add § 42.57 to read as follows:
§ 42.57
Privilege for patent practitioners.
(a) Privileged communications. A
communication between a client and a
VerDate Sep<11>2014
12:33 Oct 17, 2016
Jkt 241001
domestic or foreign patent practitioner
that is reasonably necessary or incident
to the scope of the patent practitioner’s
authority shall receive the same
protections of privilege as if that
communication were between a client
and an attorney authorized to practice
in the United States, including all
limitations and exceptions.
(b) Definitions. The term ‘‘domestic
patent practitioner’’ means a person
who is registered by the United States
Patent and Trademark Office to practice
before the agency under section 11.6.
‘‘Foreign patent practitioner’’ means a
person who is authorized to provide
legal advice on patent matters in a
foreign jurisdiction, provided that the
jurisdiction establishes professional
qualifications and the practitioner
satisfies them, and regardless of whether
that jurisdiction provides privilege or an
equivalent under its laws.
Dated: October 12, 2016.
Michelle K. Lee,
Under Secretary of Commerce for Intellectual
Property and Director of the United States
Patent and Trademark Office.
[FR Doc. 2016–25141 Filed 10–17–16; 8:45 am]
BILLING CODE 3510–16–P
LIBRARY OF CONGRESS
Copyright Royalty Board
37 CFR Part 385
[Docket No. 16–CRB–0003–PR (2018–2022)]
Determination of Rates and Terms for
Making and Distributing Phonorecords
(Phonorecords III); Comment Period
Extension
Copyright Royalty Board,
Library of Congress.
ACTION: Proposed rule; extension of
comment period for reply comments.
AGENCY:
The Copyright Royalty Judges
announce that they will accept reply
comments in response to comments
they received about a proposed rule
regarding rates and terms applicable
during the upcoming rate period for the
section 115 statutory license for making
and distributing phonorecords of
nondramatic musical works.
DATES: Reply comments for the
proposed rule published July 25, 2016
(81 FR 48371) are due no later than
November 17, 2016.
ADDRESSES: The proposed rule and the
comments filed in response to it are
posted on the agency’s Web site
(www.loc.gov/crb). The proposed rule is
also posted at Regulations.gov
(www.regulations.gov). Interested
SUMMARY:
PO 00000
Frm 00014
Fmt 4702
Sfmt 4702
71657
parties may submit reply comments via
email to crb@loc.gov. Those who choose
not to submit reply comments via email
should see How to Submit Reply
Comments in the SUPPLEMENTARY
INFORMATION section below for online
and physical addresses and further
instructions.
FOR FURTHER INFORMATION CONTACT:
Kimberly Whittle, Attorney Advisor, by
telephone at (202) 707–7658, or by
email at crb@loc.gov.
SUPPLEMENTARY INFORMATION: On July
25, 2016, the Judges published a
proposed rule and requested comments.
81 FR 48371. The proposed rule was
based upon a partial settlement 1
regarding copyright royalty rates and
terms applicable during the upcoming
rate period for the section 115 statutory
license for making and distributing
phonorecords of nondramatic musical
works. See Joint Motion to Adopt Partial
Settlement, Docket No. 16–CRB–0003–
PR (2018–2022) (June 15, 2016).
On or before August 24, 2016, the
Judges received two timely comments,
one from the American Association of
Independent Music (A2IM) that
supported it and one from Sony Music
Entertainment (‘‘Sony’’) that supported
it in part and opposed it in part.
On August 30, 2016, the National
Music Publishers’ Association and the
Nashville Songwriters Association
International filed a joint Motion for
Leave to Respond to the Comments and
Objections of Sony Music Entertainment
Concerning Proposed Settlement (Joint
Motion). In the interest of promoting a
more complete record with regard to the
proposed rule, the Judges will grant the
Joint Motion. In addition, the Judges
hereby announce that they will accept,
without additional motions required,
additional reply comments, if any, to
the comments filed by A2IM and Sony.
The reply comments, if any, must be
submitted no later than November 17,
2016.
How To Submit Reply Comments
Interested members of the public must
submit reply comments to only one of
the following addresses. If not
submitting by email or online,
commenters must submit an original of
their reply comments, five paper copies,
and an electronic version in searchable
PDF format on a CD.
Email: crb@loc.gov; or
Online: https://www.regulations.gov; or
1 The participants filing the motion were Church
Music Publishers Association, Nashville
Songwriters Association International, National
Music Publishers Association, Harry Fox Agency,
and Songwriters of North America, and licensees
Universal Music Group and Warner Music Group.
E:\FR\FM\18OCP1.SGM
18OCP1
Agencies
[Federal Register Volume 81, Number 201 (Tuesday, October 18, 2016)]
[Proposed Rules]
[Pages 71653-71657]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-25141]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
37 CFR Part 42
[Docket No. PTO-P-2016-0029]
RIN 0651-AD10
Rule Recognizing Privileged Communications Between Clients and
Patent Practitioners at the Patent Trial and Appeal Board
AGENCY: Patent Trial and Appeal Board, United States Patent and
Trademark Office, U.S. Department of Commerce.
ACTION: Proposed rule.
-----------------------------------------------------------------------
SUMMARY: This proposed rule would amend the rules of practice before
the Patent Trial and Appeal Board to recognize that, in connection with
discovery conducted in certain proceedings at the United States Patent
and Trademark Office (USPTO or Office), communications between U.S.
[[Page 71654]]
patent agents or foreign patent practitioners and their clients are
privileged to the same extent as communications between clients and
U.S. attorneys. The rule would apply to inter partes review, post-grant
review, the transitional program for covered business method patents,
and derivation proceedings. This rule would clarify the protection
afforded to such communications, which is currently not addressed in
the rules governing Board proceedings at the USPTO. This new rule will
not affect the duty of disclosure and candor before the Office under 37
CFR 1.56.
DATES: Comment date: The Office solicits comments from the public on
this proposed rulemaking. Written comments must be received on or
before December 19, 2016 to ensure consideration.
ADDRESSES: Comments should be sent by electronic mail message over the
Internet addressed to: acprivilege@uspto.gov. Comments may also be
submitted by postal mail addressed to: Mail Stop OPIA Director of the
United States Patent and Trademark Office, P.O. Box 1450, Alexandria,
VA 22313-1450, marked to the attention of ``Soma Saha, Patent Attorney,
Patent Trial Proposed Rule on Privilege.''
Comments may also be sent by electronic mail message over the
Internet via the Federal eRulemaking Portal at https://www.regulations.gov. See the Federal eRulemaking Portal Web site for
additional instructions on providing comments via the Federal e-
Rulemaking Portal.
Although comments may be submitted by postal mail, the Office
prefers to receive comments by electronic mail message to be able to
more easily share all comments with the public. The Office prefers the
comments to be submitted in plain text, but also accepts comments
submitted in ADOBE[supreg] portable document format or MICROSOFT
WORD[supreg] format. Comments not submitted electronically should be
submitted on paper in a format that accommodates digital scanning into
ADOBE[supreg] portable document format.
The comments will be available for public inspection at the Office
of Policy and International Affairs, currently located in Madison East,
Second Floor, 600 Dulany Street, Alexandria, Virginia. Comments also
will be available for viewing via the Office's Internet Web site at
https://www.uspto.gov/patents/law/comments/index.jsp and at https://www.regulations.gov. Because comments will be made available for public
inspection, information that the submitter does not desire to be made
public, such as address or phone number, should not be included in the
comments.
FOR FURTHER INFORMATION CONTACT: Soma Saha, Patent Attorney, by email
at soma.saha@uspto.gov or by telephone at (571) 272-8652; or Edward
Elliott, Attorney Advisor, by email at edward.elliott@uspto.gov or by
telephone at (571) 272-7024.
SUPPLEMENTARY INFORMATION:
Purpose: This proposed rule would amend the rules of practice
before the Patent Trial and Appeal Board (PTAB) to recognize that
communications between non-attorney U.S. patent agents or foreign
patent practitioners and their clients that pertain to authorized
practice before the United States Patent and Trademark Office (Office
or USPTO) are privileged to the same extent as communications of that
sort conducted between clients and U.S. attorneys. Under the proposed
rule, those communications would be protected from discovery in trial
practice proceedings at the USPTO. The proposed rule would apply to
inter partes review (IPR), post-grant review (PGR), the transitional
program for covered business method patents (CBM), and derivation
proceedings. Currently, the rules governing proceedings at the USPTO do
not address the privilege of communications with patent practitioners,
and questions regarding that matter are decided on a case-by-case basis
under common law principles. This new rule will not affect the duty of
disclosure and candor before the Office under 37 CFR 1.56.
Background: Within this notice, the term ``patent practitioner''
includes both those authorized to practice patent matters before the
USPTO and those authorized to practice patent matters in foreign
jurisdictions. When referring to these groups separately, the terms
``U.S. or domestic patent practitioners'' and ``foreign patent
practitioners'' will be used, respectively.
In February 2015, the USPTO held a roundtable and solicited
comments on attorney-client privilege issues. See Notice of Roundtable
and Request for Comments on Domestic and International Issues Related
to Privileged Communications Between Patent Practitioners and Their
Clients, 80 FR 3953 (Jan. 26, 2015). As part of that process, the USPTO
requested comments on whether it should recognize that communications
between patent applicants and owners and their U.S. patent agents or
foreign patent practitioners are privileged to the same extent as
communications between U.S. patent attorneys and patent applicants and
owners. Respondents unanimously supported a rule recognizing such
privilege. See USPTO, Summary of Roundtable and Written Comments,
available at https://www.uspto.gov/sites/default/files/documents/Summary%20of%20Privileged%20Communication%20Roundtable.pdf (``Privilege
Report'').
The USPTO administers various proceedings that entail discovery
procedures, namely the IPR, PGR, and transitional program for CBM
patents. In addition, the derivation proceedings provided for by the
Leahy-Smith America Invents Act, Public Law 112-29, 125 Stat. 284
(2011) (AIA) permit discovery. Questions regarding privilege issues may
arise in the course of discovery, and as some roundtable commenters
noted, rules regarding privilege for U.S. patent agents and foreign
practitioners during discovery in PTAB proceedings are not well
defined.
Current Practice: PTAB proceedings are subject to the Federal Rules
of Evidence (FRE), which include rules on attorney-client privilege.
See 37 CFR 42.62(a). Accordingly, privilege may be asserted in PTAB
proceedings by licensed attorneys. However, the FRE does not explicitly
address privilege for communications with non-attorney U.S. patent
agents or with foreign patent practitioners.
The rules governing PTAB practice likewise do not address this
matter, and when it arises, PTAB Administrative Law Judges make legal
determinations as to which communications may be protected from
disclosure on a case-by-case basis, based on common law. See GEA
Process Engineering, Inc. v. Steuben Foods, Inc., IPR2014-00041, Paper
117 (PTAB 2014). U.S. courts have devised several different approaches
to determine under what circumstances communications with these
practitioners are privileged. As the Privilege Report notes, the common
law on privilege for domestic and foreign patent practitioners varies
across jurisdictions. Different approaches are taken, and results
sometimes conflict. This may lead to administrative inefficiencies and
inconsistencies in outcomes, as PTAB must select which set of common
law rules to follow. (It is also noted that Administrative Law Judges
in other agencies recognize certain confidential communications with a
patent agent as privileged. See, e.g., USITC Inv. No. 337-TA-339, slip
op. at 2, 1992 WL 811804 (ITC 1992) (finding that confidential
communications between a U.S. patent agent and his client in connection
with
[[Page 71655]]
a patent prosecution are privileged).) The Federal Circuit recently
recognized that attorney-client privilege applies to U.S. patent agents
acting within the scope of their authorized practice. See In re Queen's
University at Kingston, PARTEQ Research and Development Innovations,
No. 2015-145 (Fed. Cir. 2016).
The Office has strong policy reasons to establish a privilege rule
governing trial proceedings before PTAB. Such a rule would help ensure
consistent outcomes with respect to privilege matters that arise at the
Office, would improve public understanding of how privilege questions
are decided before PTAB, and would help further judicial economy by
providing PTAB judges with a clear, concise statement of when privilege
applies.
Public Comments: In August 2015, the USPTO published in the Federal
Register a proposed rule amending the rules for trial practice before
the Office. See Amendments to the Rules of Practice for Trials Before
the Patent Trial and Appeal Board, 80 FR 50719 (Aug. 20, 2015).
Included in that proposed rule was a request for comments on the
advisability of a privilege rule for PTAB proceedings. The comments
submitted in response to that request are available on the USPTO Web
site at https://www.uspto.gov/patents-application-process/patent-trial-and-appeal-board/comments-amendments-rules-practice-trials.
Those responding to the request universally agreed that a privilege
rule for PTAB proceedings should be promulgated. Respondents
overwhelmingly favored promulgating such a rule, with some noting that
it would lead to clarity and consistency and ``can reduce uncertainty
and mitigate discovery costs.'' See Letter from Frederick W. Mau II on
behalf of Toyota Motor Corp., David B. Kelley on behalf of Ford Motor
Co., and Mark Duell on behalf of American Honda Motor Co., Inc., RE:
Comments on Amendments to the Rules of Practice for Trials Before the
Patent Trial and Appeal Board, p. 4-5 (Oct. 16, 2015). Others suggested
that ``[i]f patent agents are not entitled to have their communications
be considered privileged, however, then their utility--and associated
cost savings for stakeholders--is lost.'' See Letter from Sharon A.
Israel, President of the American Intellectual Property Law Assoc., RE:
Response to Proposed ``Amendments to the Rules of Practice for Trials
Before the Patent Trial and Appeal Board,'' 80 FR 50720 (August 20,
2015), p. 15-16 (Oct. 21, 2015).
Commenters said it ``would be particularly useful for patent
agents['] communications to be explicitly protected in the discovery
rules for post-grant proceedings (e.g., inter parties [sic] review)
before the USPTO.'' See Letter from Dorothy R. Auth, President of the
New York Intellectual Property Law Assoc., RE: NYIPLA Comments in
Response to ``Amendments to the Rules of Practice for Trials Before the
Patent Trial and Appeal Board,'' Federal Register Notice, August 20,
2015, Vol. 80, No. 161 (80 FR 50720), p. 6-9 (Nov. 18, 2015).
Commenters suggested that the rule should extend at least to
communications made in connection with acts that patent agents are
authorized to perform in their particular jurisdictions, such as
prosecuting patent applications. The USPTO agrees that the scope of a
privilege rule should be defined by the activities that the agent is
authorized to carry out. Others suggested that it should be ``a simple
rule . . . that explicitly recognize[s] privilege for communications
between patent applicants or owners and their domestic patent agents or
foreign professional patent practitioners under the same circumstances
as such privilege is recognized for communications between applicants
or owners and U.S. attorneys.'' See Letter from Andrew D. Meikle,
President of the U.S. Section of the International Federation of
Intellectual Property Attorneys (FICPI), RE: Comments on ``Recognizing
Privilege for Communications With Domestic Patent Agents and Foreign
Patent Practitioners'', p. 4 (Nov. 24, 2015).
According to these comments, ``[t]his approach would provide the
greatest uniformity and certainty, and avoid the need for the PTAB to
engage in complex fact based analysis regarding application of the
privilege under the common law.'' Id. These views were echoed by a law
professor who has studied this issue since 2008:
The privilege should be as broad as the ordinary attorney-client
privilege. It should cover not only U.S. patent agents, but also
foreign legal representatives. While the best solution would be a
privilege that applied in all legal tribunals--not only the PTAB,
but also federal and state courts--adoption of a privilege only for
the PTAB would be a valuable first step toward this goal.
See Letter from John T. Cross, Professor of Law at University of
Louisville, Possible Adoption of a Legal Representation Privilege in
Matters Before the Patent Trial and Appeal Board, p. 2 (Sep. 9, 2015).
The USPTO agrees with these views and believes the proposed rule
reflects them. As a policy matter, open and frank discussions between
practitioners and clients promotes effective legal representation
before the Office.
Discussion of Specific Rules
Taking into consideration comments from the public and insight
gained from practice, the Office proposes to amend 37 CFR 42 to add new
section 42.57 that clarifies which patent practitioners are eligible
for assertions of attorney-client privilege.
The term ``patent practitioner'' is used to conform with existing
terminology and avoid confusion with other terms used around the world,
such as ``IP Advisor'' or ``Patent Advisor.'' It fits with practice
elsewhere in Title 37, which refers to domestic ``patent
practitioners,'' i.e., U.S. patent agents and patent attorneys
registered under 37 CFR 11.6. This narrower meaning is appropriate for
most sections of Title 37, which deal with practitioners admitted to
practice before the USPTO. For the new rule only, the term also
includes comparable foreign counterparts practicing before foreign
patent offices.
The rule would provide that the privilege only applies where the
practitioner performs legal work authorized by the jurisdiction in
which the practitioner practices. For instance, communications between
clients and U.S. patent agents relating to patent application matters
would be protected as privileged under the rule, but communications
between these parties regarding litigation strategies would not be
protected. The proposed rule also does not recognize privilege as
applying to advice given by lay persons in jurisdictions that do not
impose professional qualifications as a requirement to practice.
However, the proposed rule can apply to communications from an in-house
counsel who performs the functions of a patent attorney under
appropriate circumstances, even though some civil law jurisdictions may
not grant in-house counsel the privilege-type protections given to
attorneys.
The Office invites the public to provide any comments on the
proposed rule to inform further action.
Costs and Benefits: This rulemaking is not economically
significant, and is not significant, under Executive Order 12866 (Sept.
30, 1993), as amended by Executive Order 13258 (Feb. 26, 2002) and
Executive Order 13422 (Jan. 18, 2007).
Rulemaking Considerations
A. Administrative Procedure Act (APA)
This proposed rule revises the rules of practice before PTAB to
recognize that
[[Page 71656]]
communications between non-attorney or foreign patent practitioners and
their clients that pertain to authorized practice before the USPTO are
privileged. The changes in this rulemaking involve rules of agency
practice and procedure and/or interpretive rules. See Nat'l Org. of
Veterans' Advocates v. Secretary of Veterans Affairs, 260 F.3d 1365,
1375 (Fed. Cir. 2001) (rule that clarifies interpretation of a statute
is interpretive); Bachow Commc'ns Inc. v. F.C.C., 237 F.3d 683, 690
(D.C. Cir. 2001) (rules governing an application process are procedural
under the Administrative Procedure Act); Inova Alexandria Hosp. v.
Shalala, 244 F.3d 342, 350 (4th Cir. 2001) (rules for handling appeals
were procedural where they did not change the substantive requirements
for reviewing claims).
Accordingly, prior notice and opportunity for public comment are
not required pursuant to 5 U.S.C. 553(b) or (c), or any other law. See
Cooper Techs. Co. v. Dudas, 536 F.3d 1330, 1336-37 (Fed. Cir. 2008)
(stating that 5 U.S.C. 553, and thus 35 U.S.C. 2(b)(2)(B), do not
require notice and comment rulemaking for ``interpretative rules,
general statements of policy, or rules of agency organization,
procedure, or practice'' (quoting 5 U.S.C. 553(b)(A))). However, the
Office chose to seek public comment before implementing the rule to
benefit from the public's input.
B. Regulatory Flexibility Act
For the reasons set forth herein, the Deputy General Counsel for
General Law of the USPTO has certified to the Chief Counsel for
Advocacy of the Small Business Administration that this proposed rule
will not have a significant economic impact on a substantial number of
small entities. See 5 U.S.C. 605(b).
The changes proposed in this rule are to revise the rules of
practice before PTAB to explicitly recognize that communications
between non-attorney or foreign patent practitioners and their clients
that pertain to authorized practice before the USPTO or foreign patent
offices are privileged and to define those persons who may avail
themselves of this privilege. These proposed changes are expected to
create no additional burden to those practicing before the Board as
this rule merely clarifies rights and protections for the practitioner
and client and does not impose a change in practice or requirements. In
fact, this rule may produce a small benefit from a reduction in
uncertainty and mitigation of discovery costs. For the foregoing
reasons, the changes proposed in this rule will not have a significant
economic impact on a substantial number of small entities.
C. Executive Order 12866 (Regulatory Planning and Review)
This rulemaking has been determined to be not significant for
purposes of Executive Order 12866 (Sept. 30, 1993).
D. Executive Order 13563 (Improving Regulation and Regulatory Review)
The Office has complied with Executive Order 13563. Specifically,
the Office has, to the extent feasible and applicable: (1) Made a
reasoned determination that the benefits justify the costs of the rule;
(2) tailored the rule to impose the least burden on society consistent
with obtaining the regulatory objectives; (3) selected a regulatory
approach that maximizes net benefits; (4) specified performance
objectives; (5) identified and assessed available alternatives; (6)
involved the public in an open exchange of information and perspectives
among experts in relevant disciplines, affected stakeholders in the
private sector and the public as a whole, and provided on-line access
to the rulemaking docket; (7) attempted to promote coordination,
simplification, and harmonization across government agencies and
identified goals designed to promote innovation; (8) considered
approaches that reduce burdens and maintain flexibility and freedom of
choice for the public; and (9) ensured the objectivity of scientific
and technological information and processes.
E. Executive Order 13132 (Federalism)
This rulemaking does not contain policies with federalism
implications sufficient to warrant preparation of a Federalism
Assessment under Executive Order 13132 (Aug. 4, 1999).
F. Executive Order 13175 (Tribal Consultation)
This rulemaking will not: (1) Have substantial direct effects on
one or more Indian tribes; (2) impose substantial direct compliance
costs on Indian tribal governments; or (3) preempt tribal law.
Therefore, a tribal summary impact statement is not required under
Executive Order 13175 (Nov. 6, 2000).
G. Executive Order 13211 (Energy Effects)
This rulemaking is not a significant energy action under Executive
Order 13211 because this rulemaking is not likely to have a significant
adverse effect on the supply, distribution, or use of energy.
Therefore, a Statement of Energy Effects is not required under
Executive Order 13211 (May 18, 2001).
H. Executive Order 12988 (Civil Justice Reform)
This rulemaking meets applicable standards to minimize litigation,
eliminate ambiguity, and reduce burden as set forth in sections 3(a)
and 3(b)(2) of Executive Order 12988 (Feb. 5, 1996).
I. Executive Order 13045 (Protection of Children)
This rulemaking does not concern an environmental risk to health or
safety that may disproportionately affect children under Executive
Order 13045 (Apr. 21, 1997).
J. Executive Order 12630 (Taking of Private Property)
This rulemaking will not affect a taking of private property or
otherwise have taking implications under Executive Order 12630 (Mar.
15, 1988).
K. Congressional Review Act
Under the Congressional Review Act provisions of the Small Business
Regulatory Enforcement Fairness Act of 1996 (5 U.S.C. 801 et seq.),
prior to issuing any final rule, the USPTO will submit a report
containing the rule and other required information to the United States
Senate, the United States House of Representatives, and the Comptroller
General of the Government Accountability Office. The changes in this
final rule are not expected to result in an annual effect on the
economy of 100 million dollars or more, a major increase in costs or
prices, or significant adverse effects on competition, employment,
investment, productivity, innovation, or the ability of United States-
based enterprises to compete with foreign-based enterprises in domestic
and export markets. Therefore, this final rule is not a ``major rule''
as defined in 5 U.S.C. 804(2).
L. Unfunded Mandates Reform Act of 1995
The changes set forth in this rulemaking do not involve a Federal
intergovernmental mandate that will result in the expenditure by State,
local, and tribal governments, in the aggregate, of 100 million dollars
(as adjusted) or more in any one year, or a Federal private sector
mandate that will result in the expenditure by the private sector of
100 million dollars (as adjusted) or more in any one year, and will not
significantly or uniquely affect small governments. Therefore, no
actions are necessary under the provisions of the
[[Page 71657]]
Unfunded Mandates Reform Act of 1995. See 2 U.S.C. 1501 et seq.
M. National Environmental Policy Act
This rulemaking will not have any effect on the quality of the
environment and is thus categorically excluded from review under the
National Environmental Policy Act of 1969. See 42 U.S.C. 4321 et seq.
N. National Technology Transfer and Advancement Act
The requirements of section 12(d) of the National Technology
Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) are not
applicable because this rulemaking does not contain provisions which
involve the use of technical standards.
O. Paperwork Reduction Act
The Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3549) requires
that the Office consider the impact of paperwork and other information
collection burdens imposed on the public. This proposed rule not does
not involve any new information collection requirements that are
subject to review by the Office of Management and Budget (OMB) under
the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3549). Any
information collections associated with this rule have been previously
approved under OMB control number 0651-0069.
Notwithstanding any other provision of law, no person is required
to respond to, nor shall any person be subject to, a penalty for
failure to comply with a collection of information subject to the
requirements of the Paperwork Reduction Act unless that collection of
information displays a currently valid OMB control number.
List of Subjects in 37 CFR Part 42
Administrative practice and procedure, inventions and patents.
For the reasons set forth in the preamble, 37 CFR part 42 is
proposed to be amended as follows:
PART 42--TRIAL PRACTICE BEFORE THE PATENT TRIAL AND APPEAL BOARD
0
1. The authority citation for 37 CFR Part 42 continues to read as
follows:
Authority: 35 U.S.C. 2(b)(2), 6, 21, 23, 41, 135, 311, 312,
316, 321-326; Pub. L. 112-29, 125 Stat. 284; and Pub. L. 112-274,
126 Stat. 2456.
0
2. Add Sec. 42.57 to read as follows:
Sec. 42.57 Privilege for patent practitioners.
(a) Privileged communications. A communication between a client and
a domestic or foreign patent practitioner that is reasonably necessary
or incident to the scope of the patent practitioner's authority shall
receive the same protections of privilege as if that communication were
between a client and an attorney authorized to practice in the United
States, including all limitations and exceptions.
(b) Definitions. The term ``domestic patent practitioner'' means a
person who is registered by the United States Patent and Trademark
Office to practice before the agency under section 11.6. ``Foreign
patent practitioner'' means a person who is authorized to provide legal
advice on patent matters in a foreign jurisdiction, provided that the
jurisdiction establishes professional qualifications and the
practitioner satisfies them, and regardless of whether that
jurisdiction provides privilege or an equivalent under its laws.
Dated: October 12, 2016.
Michelle K. Lee,
Under Secretary of Commerce for Intellectual Property and Director of
the United States Patent and Trademark Office.
[FR Doc. 2016-25141 Filed 10-17-16; 8:45 am]
BILLING CODE 3510-16-P